SCHEMBL645320

SCHEMBL645320

CCS(=O)(=O)c1cccc(-c2cc(C(=O)N3CCN(C)CC3)cc3[nH]c4ncc(C)cc4c23)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BTK Q06187 8/20 0.60
FYN P06241 2/20 0.60
MAP3K11 Q16584 2/20 0.60
PLK4 O00444 1/20 0.60
CHEK1 O14757 1/20 0.60
AURKA O14965 1/20 0.60
EPHB6 O15197 1/20 0.60
RPS6KA4 O75676 1/20 0.60
STK16 O75716 1/20 0.60
STK10 O94804 1/20 0.60
ABL1 P00519 1/20 0.60
EGFR P00533 1/20 0.60
NTRK1 P04629 1/20 0.60
LCK P06239 1/20 0.60
YES1 P07947 1/20 0.60
LYN P07948 1/20 0.60
RET P07949 1/20 0.60
HCK P08631 1/20 0.60
PDGFRB P09619 1/20 0.60
BCR P11274 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2612678 0.86 BTK (0.76) BTKFYNMAP3K11PLK4CHEK1
SCHEMBL646289 0.86 PLK4 (0.53) BTKFYNMAP3K11PLK4CHEK1
SCHEMBL644220 0.85 PLK4 (0.55) BTKFYNMAP3K11PLK4CHEK1
SCHEMBL645029 0.85 CDK9 (0.54) BTKFYNMAP3K11PLK4CHEK1
SCHEMBL645095 0.84 MAP3K11 (0.58) BTKFYNMAP3K11PLK4CHEK1
SCHEMBL645340 0.84 PLK4 (0.53) BTKFYNMAP3K11PLK4CHEK1
SCHEMBL645622 0.83 PLK4 (0.54) BTKFYNMAP3K11PLK4CHEK1
SCHEMBL647084 0.80 CHEK1 (0.54) BTKFYNMAP3K11PLK4CHEK1
SCHEMBL646306 0.79 PLK4 (0.71) BTKFYNMAP3K11PLK4CHEK1
SCHEMBL645077 0.79 CHEK1 (0.54) BTKFYNMAP3K11PLK4CHEK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100190816-A1 KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-07-29 US claimed
EP-2145877-A2 Aurora Kinase inhibitors Takeda Pharmaceutical Company Limited (JP) 2010-01-20 EP claimed
EP-2081930-A2 KINASE INHIBITORS Takeda San Diego, Inc. (US) 2009-07-29 EP claimed
US-20090156557-A1 KINASE INHIBITORS TAKEDA SAN DIEGO, INC. (US) 2009-06-18 US claimed
CN-101356172-A Kinase inhibitors TAKEDA SAN DIEGO INC (US) 2009-01-28 CN claimed
WO-2008045834-A2 KINASE INHIBITORS TAKEDA SAN DIEGO, INC. (US) 2008-04-17 WO claimed
US-20070117816-A1 KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-05-24 US claimed
US-8318939-B2 Kinase inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-11-27 US disclosed
US-8318939-B2 Kinase inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-11-27 US disclosed
US-8318939-B2 Kinase inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-11-27 US disclosed
US-20120252761-A1 KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-04 US disclosed
US-20120252761-A1 KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-04 US disclosed
US-20120252761-A1 KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-04 US disclosed
WO-2008045834-A2 KINASE INHIBITORS TAKEDA SAN DIEGO, INC. (US) 2008-04-17 WO disclosed
WO-2008045834-A2 KINASE INHIBITORS TAKEDA SAN DIEGO, INC. (US) 2008-04-17 WO disclosed
US-20070117816-A1 KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-05-24 US disclosed
US-20070117816-A1 KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-05-24 US disclosed
US-20070117816-A1 KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-05-24 US disclosed
WO-2007044779-A1 KINASE INHIBITORS TAKEDA SAN DIEGO, INC. (US) 2007-04-19 WO disclosed
WO-2007044779-A1 KINASE INHIBITORS TAKEDA SAN DIEGO, INC. (US) 2007-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070117816-A1 KINASE INHIBITORS MAP3K20, MAP3K19, MAP3K1 BTK 112/4885FYN 367/4885MAP3K11 14/4885
US-20090156557-A1 KINASE INHIBITORS MAP3K20, MAP3K1, MAP3K19 BTK 143/4885FYN 362/4885MAP3K11 15/4885
US-20100190816-A1 KINASE INHIBITORS MAP3K20, MAP3K19, MAP3K1 BTK 112/4885FYN 367/4885MAP3K11 14/4885
US-20120252761-A1 KINASE INHIBITORS MAP3K20, MAP3K1, MAP3K19 BTK 143/4885FYN 362/4885MAP3K11 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.